Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 30 peer-reviewed journal articles Updated
Oncology · Invasive Ductal Carcinoma

How Is IDC Recurrence Risk Estimated in Early Breast Cancer?

At a Glance

Recurrence risk in early-stage invasive ductal carcinoma is estimated by combining tumor size and lymph-node status with grade, hormone receptor (ER/PR) and HER2 results, lymphovascular invasion, age, genomic testing, and response to treatment; no single feature can predict one person’s outcome.

In this answer

6 sections

01

The Baseline: AJCC Prognostic Staging

02

Additional Factors That Influence Risk

03

Genomic Assays (For HR+/HER2- Disease)

04

Neoadjuvant Treatment: Response as a Risk Predictor

05

Understanding the Numbers: Relative vs. Absolute Risk

06

The Limits of Online Calculators

If you have been diagnosed with early-stage, non-metastatic invasive ductal carcinoma (IDC), estimating the chance of the cancer returning involves much more than looking at a single feature like tumor size or grade. Instead, your care team calculates recurrence risk by weighing anatomic factors (how much cancer there is) alongside biologic factors (how the cancer behaves) and your response to treatment. When these factors seem to conflict—such as having a small tumor (usually lower risk) but a high grade (usually higher risk)—doctors do not simply let one cancel the other out. Instead, they use a combination of prognostic staging, microscopic findings, genomic assays, and clinical tools to build a comprehensive, personalized estimate of your risk.

The Baseline: AJCC Prognostic Staging

Historically, doctors relied primarily on anatomic TNM staging (Tumor size, Node involvement, and Metastasis). Today, the modern staging system (the AJCC 8th edition) actively combines these anatomic factors with your tumor’s biology to create a prognostic stage group [1][2]. This biology includes estrogen and progesterone receptor (ER/PR) status, HER2 status, and histologic grade (how abnormal the cells look and how actively they are dividing).

When factors conflict, they are synthesized into this prognostic stage [3]. For example, a small tumor might be assigned a higher stage if it has aggressive features, such as being grade 3 or triple-negative (lacking ER, PR, and HER2 receptors) [4]. Conversely, a larger tumor might be staged lower if it is strongly hormone receptor-positive (HR+) [5]. However, one favorable marker does not completely erase anatomic risks; having more involved lymph nodes still carries a higher risk regardless of favorable biology [6].

Additional Factors That Influence Risk

Not every clinical feature is folded directly into your official prognostic stage. Doctors also look at independent factors that refine your recurrence estimate and influence treatment decisions:

  • Lymphovascular Invasion (LVI): This is a microscopic finding where cancer cells are seen in the tiny blood or lymph vessels near the tumor. LVI may add prognostic information and suggest a higher risk, but it does not automatically change your stage or prove the cancer has spread beyond the breast [7][8].
  • Age and Menopausal Status: Younger age or premenopausal status can independently influence risk and treatment decisions, particularly regarding how intensely hormone suppression is used [7].
  • Recurrence Timing: A recurrence can be local (in the breast), regional (in nearby lymph nodes), or distant (spread to other organs). For HR-positive cancers, the risk of distant recurrence can persist well beyond 5 years, which is why extended endocrine (hormone) therapy is sometimes recommended based on individual risk [9][10].

Genomic Assays (For HR+/HER2- Disease)

For many patients with HR-positive, HER2-negative early breast cancer, clinical features are evaluated alongside genomic assays, such as Oncotype DX or MammaPrint [11][12]. These tests analyze the activity of specific genes within the tumor to predict recurrence risk and determine if chemotherapy will be beneficial.

  • Refining Risk: A low genomic score may support omitting chemotherapy when the patient fits the validated group and the care team agrees [12]. However, a low score does not mean zero recurrence risk; clinical risks, like a large tumor size or high grade, still matter [13].
  • Age and Assay Results: For premenopausal women (or women under 50) with 1 to 3 positive lymph nodes, trials using the Oncotype DX test showed a benefit to chemotherapy even with a low score [14]. This benefit may be partly related to ovarian function suppression caused by the chemotherapy itself [15].
  • (Note: Genomic assays are not typically used to guide treatment for HER2-positive or triple-negative breast cancers [16].)

Neoadjuvant Treatment: Response as a Risk Predictor

If you receive medication (like chemotherapy or targeted therapy) before surgery—known as neoadjuvant therapy—the way the tumor responds provides powerful clues about your future risk.

  • Pathologic Complete Response (pCR): In common use, a pCR means no residual invasive cancer is found in the breast and sampled regional lymph nodes at the time of surgery, though noninvasive cells (like DCIS) may still be present [17][18]. Achieving a pCR is generally linked to better long-term outcomes, particularly in HER2-positive and triple-negative breast cancers [19].
  • Residual Cancer Burden (RCB): If invasive cancer remains, pathologists use a standardized system to calculate an RCB score. A higher amount of residual cancer generally means a higher estimated recurrence risk [20]. Residual disease is not an automatic fate, but it provides information that may change your management. Depending on your subtype, doctors might recommend specific additional treatments—such as T-DM1 for selected HER2-positive cancers [21], or capecitabine for selected HER2-negative or triple-negative cancers [22]—to further lower your risk.

Understanding the Numbers: Relative vs. Absolute Risk

When doctors or online tools give you numbers, it is crucial to understand the endpoint (e.g., local recurrence vs. distant recurrence) and the time horizon (e.g., 5-year vs. 10-year risk) [23]. You must also distinguish between relative risk and absolute risk:

  • Relative Risk compares two groups. If a treatment cuts a 10% 5-year distant recurrence risk in half, that is a 50% relative reduction.
  • Absolute Risk looks at the actual percentage points. Dropping a 10% risk to 5% is an absolute benefit of 5 percentage points [24][23].

Patients should always ask for the absolute benefit to understand exactly how much a therapy is likely to help them.

The Limits of Online Calculators

Tools like PREDICT are frequently used to combine age, tumor size, grade, and receptor status to estimate survival and treatment benefits [25][26]. While helpful, these tools have important limitations:

  • They estimate survival, not recurrence: PREDICT mostly models overall survival or breast-cancer-specific mortality, which are different endpoints than a cancer recurrence [27][28].
  • They are not perfect for everyone: Validation studies show these tools can sometimes underestimate risk, especially at the extremes of age (like women under 40 or older populations) or for specific tumor subtypes [29][30].

Ultimately, no model or calculator can give you a 100% guarantee. A risk estimate is a statistical probability based on populations of people with similar cancers; it cannot predict the exact future of an individual person. It is a tool designed to help you and your care team make the most informed choices about your treatment.

Common questions in this guide

Which features are used to estimate recurrence risk in invasive ductal carcinoma?
Doctors combine tumor size, lymph-node involvement, grade, ER/PR and HER2 status, and whether cancer has spread with findings such as lymphovascular invasion, age, and menopausal status. The response to treatment and, for some hormone receptor-positive/HER2-negative cancers, a genomic assay can further refine the estimate.
What is an AJCC prognostic stage, and why does it matter?
A prognostic stage combines anatomic features—tumor size, lymph nodes, and metastasis—with tumor grade and ER, PR, and HER2 biology. It helps explain why a small but aggressive tumor can carry more risk, while favorable hormone receptors may lower risk without eliminating the effect of involved nodes.
What does a low Oncotype DX or MammaPrint score mean?
For selected hormone receptor-positive, HER2-negative early breast cancers, a low genomic score may support omitting chemotherapy when the patient fits the group in which the test was validated. It does not mean the chance of recurrence is zero, and age, menopausal status, lymph nodes, tumor size, and grade still matter.
How does treatment response before surgery change recurrence risk?
A pathologic complete response means no residual invasive cancer is found in the breast or sampled regional lymph nodes at surgery, although noninvasive cells may remain. It is generally associated with better outcomes, while a higher residual cancer burden indicates more remaining disease and may lead to additional treatment depending on the cancer subtype.
Does PREDICT tell me my chance of recurrence?
Tools such as PREDICT mainly estimate survival or breast-cancer-specific mortality rather than the chance that cancer will return. A number from one of these tools should not automatically be treated as a recurrence percentage, and results may be less reliable for some ages or tumor subtypes.
Why should I ask whether a risk number is absolute or relative?
Relative risk compares one group with another, whereas absolute risk states the actual percentage-point change over a defined time. For example, lowering a 5-year risk from 10% to 5% is a 50% relative reduction and a 5-percentage-point absolute reduction.
Does lymphovascular invasion mean my breast cancer has spread?
Lymphovascular invasion means cancer cells were seen in small blood or lymph vessels near the tumor under the microscope. It may raise recurrence risk, but it does not by itself prove that cancer has spread beyond the breast or automatically change the stage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do my specific anatomic factors (tumor size, nodal status) and biologic factors (grade, ER/PR, HER2) combine to determine my overall prognostic stage?
  2. 2.Based on my pathology report, is there evidence of lymphovascular invasion (LVI), and how does that microscopic finding specifically influence my risk estimate?
  3. 3.If we are using a genomic assay like Oncotype DX, how does my menopausal status or age change the way we interpret the score for chemotherapy benefit?
  4. 4.If I received treatment before surgery, what was my residual cancer burden (RCB) class, and does this result make me eligible for additional targeted treatments or chemotherapies?
  5. 5.When you quote a risk percentage, is that number referring to local recurrence, distant recurrence, or overall survival, and what time horizon (e.g., 5 or 10 years) does it cover?
  6. 6.For the adjuvant treatment you are recommending, what is the absolute percentage-point reduction in my risk of recurrence, rather than just the relative reduction?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Breast Cancer Stage Change After Surgery or Treatment?Does Lymphovascular Invasion Change Breast Cancer Treatment?How Common Is Invasive Ductal Carcinoma Compared With DCIS?How Does Oncotype DX Guide Chemotherapy by Node Status?How Is IDC Diagnosed Following an Abnormal Mammogram?Should I Get a Second Opinion for Invasive Ductal Cancer?What Do ITCs and Micrometastases Mean in Breast Cancer?What Are IDC Symptoms to Watch After a Normal Mammogram?What Causes Invasive Ductal Carcinoma? Risk FactorsWhat Do Core Biopsy Results Mean in Invasive Ductal Cancer?What Does an Equivocal or Conflicting HER2 Test Mean?What Does ER-Low Positive Mean in Invasive Ductal Carcinoma?What Does ER-Positive, PR-Negative IDC Mean for Treatment?What Does the Ki-67 Score Mean in Invasive Ductal Carcinoma?HER2-Low and HER2-Ultralow: What Do They Mean in IDC?What Do Surgical Margins Mean After IDC Breast Surgery?Do I Need Staging Scans for Invasive Ductal Carcinoma?MammaPrint vs. Oncotype DX: When Is Each Used for IDC?Who Needs Oncotype DX for Invasive Ductal Breast Cancer?

References

References (30)
  1. 1

    Anatomy and Breast Cancer Staging: Is It Still Relevant?

    Plichta JK, Campbell BM, Mittendorf EA, Hwang ES

    Surgical oncology clinics of North America 2018; (27(1)):51-67 doi:10.1016/j.soc.2017.07.010.

    PMID: 29132565
  2. 2

    Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Giuliano AE, Connolly JL, Edge SB, et al.

    CA: a cancer journal for clinicians 2017; (67(4)):290-303 doi:10.3322/caac.21393.

    PMID: 28294295
  3. 3

    Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

    Weiss A, King TA, Hunt KK, Mittendorf EA

    The Surgical clinics of North America 2018; (98(4)):687-702 doi:10.1016/j.suc.2018.03.005.

    PMID: 30005768
  4. 4

    The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.

    Tokunaga E, Ijichi H, Tajiri W, et al.

    Breast cancer (Tokyo, Japan) 2020; (27(6)):1137-1146 doi:10.1007/s12282-020-01116-w.

    PMID: 32472474
  5. 5

    Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.

    Wang M, Chen H, Wu K, et al.

    Breast (Edinburgh, Scotland) 2018; (37()):56-63 doi:10.1016/j.breast.2017.10.011.

    PMID: 29100045
  6. 6

    Association of Breast Cancer Subtypes and Clinicopathological Factors with Axillary Lymph Node Positivity Amongst Women with Breast Cancer in Rajasthan: An Observational Analytical Study.

    Patel P, Kumar N, Babu A, et al.

    Indian journal of surgical oncology 2024; (15(4)):768-776 doi:10.1007/s13193-024-01987-x.

    PMID: 39555353
  7. 7

    Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).

    Watanuki R, Sakai H, Takehara Y, et al.

    Breast cancer (Tokyo, Japan) 2025; (32(4)):757-772 doi:10.1007/s12282-025-01700-y.

    PMID: 40208504
  8. 8

    Prognosis value of lymphovascular invasion in patients with invasive ductal breast carcinoma according to lymph node metastasis status.

    da Luz FAC, da Costa Marinho E, Nascimento CP, et al.

    Ecancermedicalscience 2022; (16()):1364 doi:10.3332/ecancer.2022.1364.

    PMID: 35685958
  9. 9

    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

    Pan H, Gray R, Braybrooke J, et al.

    The New England journal of medicine 2017; (377(19)):1836-1846 doi:10.1056/NEJMoa1701830.

    PMID: 29117498
  10. 10

    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

    Burstein HJ, Lacchetti C, Anderson H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(5)):423-438 doi:10.1200/JCO.18.01160.

    PMID: 30452337
  11. 11

    Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

    Sparano JA, Gray RJ, Makower DF, et al.

    The New England journal of medicine 2015; (373(21)):2005-14 doi:10.1056/NEJMoa1510764.

    PMID: 26412349
  12. 12

    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

    Cardoso F, van't Veer LJ, Bogaerts J, et al.

    The New England journal of medicine 2016; (375(8)):717-29 doi:10.1056/NEJMoa1602253.

    PMID: 27557300
  13. 13

    Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Sparano JA, Gray RJ, Ravdin PM, et al.

    The New England journal of medicine 2019; (380(25)):2395-2405 doi:10.1056/NEJMoa1904819.

    PMID: 31157962
  14. 14

    Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

    Cooper K, Nalbant G, Essat M, et al.

    Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

    PMID: 39899163
  15. 15

    Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

    Regan MM, Francis PA, Pagani O, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2221-31 doi:10.1200/JCO.2015.64.3171.

    PMID: 27044936
  16. 16

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Andre F, Ismaila N, Allison KH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

    PMID: 35439025
  17. 17

    Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.

    Bossuyt V, Spring L

    The breast journal 2020; (26(6)):1189-1198 doi:10.1111/tbj.13864.

    PMID: 32468652
  18. 18

    Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.

    Osdoit M, Yau C, Symmans WF, et al.

    JAMA surgery 2022; (157(11)):1034-1041 doi:10.1001/jamasurg.2022.4118.

    PMID: 36069821
  19. 19

    Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

    Broglio KR, Quintana M, Foster M, et al.

    JAMA oncology 2016; (2(6)):751-60 doi:10.1001/jamaoncol.2015.6113.

    PMID: 26914222
  20. 20

    Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

    Yau C, Osdoit M, van der Noordaa M, et al.

    The Lancet. Oncology 2022; (23(1)):149-160 doi:10.1016/S1470-2045(21)00589-1.

    PMID: 34902335
  21. 21

    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

    von Minckwitz G, Huang CS, Mano MS, et al.

    The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.

    PMID: 30516102
  22. 22

    Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Masuda N, Lee SJ, Ohtani S, et al.

    The New England journal of medicine 2017; (376(22)):2147-2159 doi:10.1056/NEJMoa1612645.

    PMID: 28564564
  23. 23

    Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.

    Ethier JL, Anderson GM, Austin PC, et al.

    European journal of cancer (Oxford, England : 1990) 2021; (149()):117-127 doi:10.1016/j.ejca.2021.02.034.

    PMID: 33853037
  24. 24

    DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.

    Thorsen LB, Offersen BV, Danø H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(4)):314-20 doi:10.1200/JCO.2015.63.6456.

    PMID: 26598752
  25. 25

    An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

    Candido Dos Reis FJ, Wishart GC, Dicks EM, et al.

    Breast cancer research : BCR 2017; (19(1)):58 doi:10.1186/s13058-017-0852-3.

    PMID: 28532503
  26. 26

    Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.

    Zaguirre K, Kai M, Kubo M, et al.

    Cancer medicine 2021; (10(5)):1605-1613 doi:10.1002/cam4.3713.

    PMID: 33452761
  27. 27

    Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

    Engelhardt EG, van den Broek AJ, Linn SC, et al.

    European journal of cancer (Oxford, England : 1990) 2017; (78()):37-44 doi:10.1016/j.ejca.2017.03.015.

    PMID: 28412587
  28. 28

    Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.

    Poortmans PM, Weltens C, Fortpied C, et al.

    The Lancet. Oncology 2020; (21(12)):1602-1610 doi:10.1016/S1470-2045(20)30472-1.

    PMID: 33152277
  29. 29

    External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.

    Wang Y, Broeks A, Giardiello D, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (195()):113401 doi:10.1016/j.ejca.2023.113401.

    PMID: 37925965
  30. 30

    Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan.

    Hashiguchi H, Kouno N, Komatsu M, et al.

    Breast cancer (Tokyo, Japan) 2026; (33(2)):415-425 doi:10.1007/s12282-026-01823-w.

    PMID: 41553642

This page explains recurrence-risk estimates in early-stage invasive ductal carcinoma for informational purposes only and does not constitute medical advice. Your oncology team should interpret your pathology, genomic results, and treatment response in the context of your care.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.